Study for lupus patients not helped by steroids and 2 immunosuppressants
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older
- You have been diagnosed with lupus based on standard medical criteria
- You have active lupus symptoms, like a moderate or severe flare in the last 2 years
- You have tried steroids and at least 2 other lupus medications (one being a biologic) for 3 months each without enough improvement, or you couldn't tolerate them
- You have a positive lupus antibody test or low complement levels
- If you have lupus kidney disease, a recent biopsy confirms active kidney inflammation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people newly diagnosed with lupus (SLE) to understand how the disease develops over time. It looks at what happens before treatment starts or soon after diagnosis, and aims to improve care for lupus patients across Europe.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.